Beta Bionics Inc BBNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
-
Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance
-
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
-
BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit
-
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit
-
Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline
-
BBNX Deadline Alert: SueWallSt Reminds Beta Bionics, Inc. (BBNX) Investors of Securities Class Action Deadline on November 3, 2026
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BBNX
Trading Information
- Previous Close Price
- $17.63
- Day Range
- $17.71–18.56
- 52-Week Range
- $8.80–32.71
- Bid/Ask
- $17.60 / $18.26
- Shares Outstanding
- 53.95M
- Market Cap
- $963.48M
- Volume/Avg
- 2 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.64
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.09%
Company Profile
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 423
- Website
- https://www.betabionics.com
Valuation
|
Metric
|
BBNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.13 |
Price/Sales | 6.64 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BBNX
|
|---|---|
Quick Ratio | 7.72 |
Current Ratio | 8.88 |
Interest Coverage | — |
Quick Ratio
BBNX
Profitability
|
Metric
|
BBNX
|
|---|---|
Return on Assets (Normalized) | −16.33% |
Return on Equity (Normalized) | −18.34% |
Return on Invested Capital (Normalized) | −21.36% |
Return on Assets
BBNX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|Tr@#d%r | LOCK|lk#tD | $176B | |||
| Medtronic PLC
MDT
| LOCK|S<Sjz>> | LOCK|f#>@@ | $118B | |||
| Stryker Corp
SYK
| LOCK|dK>!?>TV | LOCK|#D | $108B | |||
| Boston Scientific Corp
BSX
| LOCK|^sJ&QMS | LOCK|mzypX | $64B | |||
| Edwards Lifesciences Corp
EW
| LOCK|>?@!^c@? | LOCK|!?#z | $50B | |||
| DexCom Inc
DXCM
| LOCK|?H&JyrM | LOCK|&Vzcm | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|DSQ%?L! | LOCK|tM! | $31B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|^p | LOCK|%& | $24B | |||
| Steris PLC
STE
| LOCK|D#^%$f? | LOCK|M?%#x | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|tw>ddpW | LOCK|PNl | $18B |
United States